PENCICLOVIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Penciclovir, and when can generic versions of Penciclovir launch?
Penciclovir is a drug marketed by Padagis Israel, Teva Pharms Usa, and Torrent. and is included in three NDAs.
The generic ingredient in PENCICLOVIR is penciclovir. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the penciclovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Penciclovir
A generic version of PENCICLOVIR was approved as penciclovir by TEVA PHARMS USA on November 9th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PENCICLOVIR?
- What are the global sales for PENCICLOVIR?
- What is Average Wholesale Price for PENCICLOVIR?
Summary for PENCICLOVIR
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,952 |
| Drug Prices: | Drug price information for PENCICLOVIR |
| What excipients (inactive ingredients) are in PENCICLOVIR? | PENCICLOVIR excipients list |
| DailyMed Link: | PENCICLOVIR at DailyMed |
Recent Clinical Trials for PENCICLOVIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Squarex, LLC | Phase 2 |
| EMS | Phase 3 |
| Novartis | Phase 4 |
Pharmacology for PENCICLOVIR
| Drug Class | Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor |
| Mechanism of Action | DNA Polymerase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for PENCICLOVIR
US Patents and Regulatory Information for PENCICLOVIR
PENCICLOVIR is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting PENCICLOVIR
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Israel | PENCICLOVIR | penciclovir | CREAM;TOPICAL | 212368-001 | Sep 27, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | PENCICLOVIR | penciclovir | CREAM;TOPICAL | 212710-001 | Nov 9, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Torrent | PENCICLOVIR | penciclovir | CREAM;TOPICAL | 216981-001 | Aug 7, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
